B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection

INTRODUCTION: Bepirovirsen (GSK3228836) is an antisense oligonucleotide that induced rapid and prolonged hepatitis B surface antigen (HBsAg) reduction with a favorable safety profile following 4 weeks of treatment in participants with chronic hepatitis B virus (HBV) infection. The objective of the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremer, Jennifer, Elston, Robert, Campbell, Fiona M., Kendrick, Stuart, Paff, Melanie, Quinn, Geoff, Theodore, Dickens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427703/
https://www.ncbi.nlm.nih.gov/pubmed/37393402
http://dx.doi.org/10.1007/s12325-023-02531-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427703/
https://www.ncbi.nlm.nih.gov/pubmed/37393402
http://dx.doi.org/10.1007/s12325-023-02531-z

Ejemplares similares